|
2012 Conference Publication Lymphocyte Counts in Patients with B-Cell Non-Hodgkin Lymphoma and Correlation with Fc Gamma Receptor PolymorphismsTalaulikar, Dipti, Cendales, Yvonne Gonzalez, Shadbolt, Bruce, Gandhi, Maher and Warren, Hilary (2012). Lymphocyte Counts in Patients with B-Cell Non-Hodgkin Lymphoma and Correlation with Fc Gamma Receptor Polymorphisms. MALDEN: WILEY-BLACKWELL. |
|
2012 Conference Publication Modulation of the unfolded protein response via XBP1 splicing: a novel mechanism that regulates Natural Killer cell effector function.Mujaj, Sally, Gandhi, Maher, Vari, Frank and Nourse, Jamie (2012). Modulation of the unfolded protein response via XBP1 splicing: a novel mechanism that regulates Natural Killer cell effector function.. 99th Annual Meeting of the American-Association-of-Immunologists, Boston Ma, May 04-08, 2012. BETHESDA: AMER ASSOC IMMUNOLOGISTS. |
|
2012 Conference Publication Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell LymphomaCamilleri, Emily T., Aya-Bonilla, Carlos A., Brown, Philip J., Banham, Alison, Marlton, Paula, Gandhi, Maher K. and Griffiths, Lyn R. (2012). Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma. 54th Annual Meeting and Exposition of the American Society of Hematology (ASH), Atlanta, GA, United States, 8-11 December 2012. Washington, DC, United States: American Society of Hematology. |
|
2012 Conference Publication Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin LymphomaGandhi, Maher K., Vari, Frank, Crooks, Pauline, Keane, Colm, Nourse, Jamie P., Seymour, Louise A., Ritchie, David, Gottlieb, David, Gill, Devinder and Jones, Kimberley (2012). Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma. 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta GA, United States, 8-11 December 2012. Washington, DC United States: American Society of Hematology. |
|
2011 Conference Publication A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A PolymorphismsHuyen Tran, , Nourse, Jamie P., Lea, Rod, Brighton, Timothy A., Grigg, Andrew, McRae, Simon, Thurley, Daniel, Gandhi, Maher and Catalano, John (2011). A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2011 Conference Publication Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6Keane, C, Shen, L, Han, E, Nourse, JP, Lea, R, Mollee, P, Gill, DS and Gandhi, MK (2011). Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2011 Conference Publication Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCLGandhi, MK, Hertzberg, MS, Han, E, Seymour, JF, Hicks, R, Gill, DS, Keane, C, Crooks, P, Radford, K and Vari, F (2011). Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2011 Conference Publication Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patientsKeane, C., Shen, L., Nourse, J., Han, E., Jones, K. and Gandhi, M. (2011). Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patients. 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, 15-18 June 2011. Oxford, United Kingdom: Oxford University Press. |
|
2010 Conference Publication Ebv-Positive Dlbcl of the Elderly Is a Distinct Clinico-Biological Entity with Poor Outcome in Chop-R Treated PatientsGandhi, M., Keane, C., Nourse, J., Jones, K., Ross, N., Han, E. and Nguyen-Van, D. (2010). Ebv-Positive Dlbcl of the Elderly Is a Distinct Clinico-Biological Entity with Poor Outcome in Chop-R Treated Patients. 15th Annual Meeting of the European-Hematology-Association, Barcelona Spain, June 10-13, 2010. Pavia, Italy: Fondazione Ferrata Storti. |
|
2009 Conference Publication EBV MicroRNA Expression in Virus Driven B-Cell Differentiation and LymphomagenesisNourse, Jamie P., Crooks, Pauline, Van, Do Nguyen, Jones, Kimberley, Ross, Nathan and Gandhi, Maher K. (2009). EBV MicroRNA Expression in Virus Driven B-Cell Differentiation and Lymphomagenesis. 51st Annual Meeting of the American-Society-of-Hematology, New Orleans La, Dec 05-08, 2009. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2009 Conference Publication Epstein-Barr Virus-specific T Cells as Therapy for Relapsed/Refractory EBV-positive LymphomasJones, Kimberley, Vari, Frank, Khanna, Rajiv, Han, Erica, Singh, Sanjleena, Ritchie, David and Gandhi, Maher K. (2009). Epstein-Barr Virus-specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas. 24th Annual Meeting of the International-Society-for-Biology-Therapy-of-Cancer, Washington Dc, Oct 29-31, 2009. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2009 Conference Publication Cell-free Epstein-Barr Virus DNA is a Specific Biomarker for Tumor Burden in EBV-associated LymphomasJones, Kimberley, Nourse, J., Crooks, P., Gottlieb, D. and Gandhi, Mahei (2009). Cell-free Epstein-Barr Virus DNA is a Specific Biomarker for Tumor Burden in EBV-associated Lymphomas. 24th Annual Meeting of the International-Society-for-Biology-Therapy-of-Cancer, Washington Dc, Oct 29-31, 2009. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2009 Conference Publication Mechanisms Underlying the Selective Impairment of Epstein Barr Virus-Nuclear Antigen I-specific Effector T Cells Observed in PTLDJones, Kimberley, Nouise, J., Morrison, L., Vari, Frank, Moss, D. and Gandhi, Mahei K. (2009). Mechanisms Underlying the Selective Impairment of Epstein Barr Virus-Nuclear Antigen I-specific Effector T Cells Observed in PTLD. 24th Annual Meeting of the International-Society-for-Biology-Therapy-of-Cancer, Washington Dc, Oct 29-31, 2009. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2009 Conference Publication Ebv Microrna Expression in An In-Vitro Model of B-Cell Differentiation and LymphomagenesisNourse, P., Jones, K., Crooks, P. and Gandhi, M. K. (2009). Ebv Microrna Expression in An In-Vitro Model of B-Cell Differentiation and Lymphomagenesis. 14th Annual Meeting of the European-Hematology-Association, Berlin Germany, Jun 04-07, 2009. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2007 Conference Publication Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patientsMollee, Peter, Hourigan, Matthew, Johnson, David, Jones, Mark, Isbel, Nikki, Hawley, Carmel, Marlton, Paula, Gandhi, Maher, Campbell, Scott and Gill, Devinder (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. 49th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA USA, 8-11 December 2007. Washington, DC USA: American Society of Hematology. |
|
2007 Conference Publication Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patientsHourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. American Transplant Congress, San Francisco, CA, USA, 5-9 May 2007. Oxford, England: Wiley-Blackwell. doi: 10.1111/j.1600-6143.2007.01811.x |
|
2007 Conference Publication Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant PatientsHourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Ghandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients. American Transplant Congress 2007, USA, 5-9 May 2007. UK: Wiley-Blackwell Publising Ltd.. doi: 10.1111/j.1600-6143.2007.01811.x |
|
2005 Conference Publication LAG-3 expressing lymphocytes suppress EBV latent membrane protein-specific T cell function in Hodgkins lymphoma patientsGandhi, M, Lambley, E, Marlton, P, Gill, D, Seymour, J, Wolf, M, Prince, M, Elliott, S and Khanna, R (2005). LAG-3 expressing lymphocytes suppress EBV latent membrane protein-specific T cell function in Hodgkins lymphoma patients. 9th International Conference on Malignant Lymphoma, Lugano Switzerland, Jun 09-11, 2005. OXFORD: OXFORD UNIV PRESS. |
|
2001 Conference Publication Significant and persistant loss of bone mineral density (BMD) in the femoral neck after haematopoietic stem cell transplantation: A prospective study.Gandhi, MK, Lekamwasam, S, Inman, , Kaptoge, S, Sizer, L, Love, S, Craig, JIO, Marcus, RE and Compston, J (2001). Significant and persistant loss of bone mineral density (BMD) in the femoral neck after haematopoietic stem cell transplantation: A prospective study.. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2001 Conference Publication Identification of novel proteins associated with the Mpl cytoplasmic domain.Gandhi, M and Drachman, JG (2001). Identification of novel proteins associated with the Mpl cytoplasmic domain.. WASHINGTON: AMER SOC HEMATOLOGY. |
